Gemcite 200 mg Injection Gemcitabine

Gemcitabine injection is administered by a qualified healthcare professional. Your doctor will determine the appropriate dosage and how often you need to receive it. This will depend on the specific condition being treated and may be adjusted periodically. You should follow your doctor's instructions precisely. Taking the medication incorrectly or in excessive amounts can lead to very serious side effects. It may take several weeks or months before you begin to see or feel the benefits of the treatment; however, do not discontinue the medication unless specifically instructed to do so by your doctor.

The most common side effects of this medication include nausea, vomiting, loss of appetite, hair loss, and a low platelet count. This medication may reduce the number of blood cells in your body (specifically red and white blood cells), thereby increasing your susceptibility to infections. Regular blood tests are required to monitor your blood cell counts, as well as your heart, liver, and blood uric acid levels.

If you have a history of heart disease, liver or kidney problems, or if you are currently taking any medications to treat an infection, please inform your doctor before starting this treatment. Many other medications may interact with or be affected by this drug; therefore, please provide your doctor with a complete list of all medications you are currently taking. Use of this medication is not recommended during pregnancy or while breastfeeding. It is essential for both men and women to use effective methods of contraception during the course of treatment to prevent pregnancy.

[Drug Name] Gemcitabine Hydrochloride

English Name: Gemcitabine Hydrochloride

Pinyin: YanSuanJiXiTaBin

[Indications] Non-small cell lung cancer, pancreatic cancer, bladder cancer, breast cancer, and other solid tumors.

[Dosage and Administration] The recommended dosage of Gemcitabine for adults is 1000 mg/m², administered as a 30-minute intravenous infusion once weekly for three consecutive weeks, followed by a one-week rest period; this four-week cycle is then repeated. The dosage should be adjusted downward as appropriate based on the patient's toxic reactions. Elderly Patients: Patients over the age of 65 generally tolerate this medication well. Although age influences the clearance rate and half-life of gemcitabine, there is no evidence indicating that dosage adjustments are required for elderly patients.

【Contraindications】 Contraindicated in patients with a known hypersensitivity to this drug.

【Precautions】 1. Contraindicated in patients with a known hypersensitivity to this drug; 2. Use should be avoided in pregnant and breastfeeding women; 3. Caution should be exercised in patients with impaired hepatic or renal function; 4. When used in combination or sequential chemotherapy regimens with other anticancer agents, the potential for cumulative myelosuppression must be considered; 5. Prolonging the drug infusion time or increasing the frequency of administration may increase drug toxicity; therefore, close monitoring—including laboratory surveillance—is required; 6. This product may cause mild drowsiness; patients should refrain from driving or operating machinery while undergoing treatment.

【Pharmacological Actions】 This product is a cell-cycle-specific antimetabolite agent that primarily targets tumor cells during the DNA synthesis phase (i.e., the S phase); under certain conditions, it can also block the progression from the G1 phase to the S phase. It demonstrates significant cytotoxic activity against various cultured human and murine tumor cell lines. Its anticancer activity is dependent on the mode of administration; for instance, daily administration may result in animal mortality, whereas anticancer activity is minimal when the drug is administered once every 3 to 4 days. When administered at non-lethal doses, it exhibits excellent anticancer activity against a wide range of murine tumors. Gemcitabine is a prodrug that serves as an excellent substrate for intracellular deoxycytidine kinase-mediated phosphorylation. Under enzymatic action, it is converted into the following metabolites: gemcitabine monophosphate (dFdCMP), gemcitabine diphosphate (dFdCDP), and gemcitabine triphosphate (dFdCTP); among these, dFdCDP and dFdC...

Product Specifications

Product Name: Gemcitabine Hydrochloride Injection (Gemcite 200 mg Injection; Gemzar)

Common Name: Gemcitabine Hydrochloride Injection

Composition: Gemcitabine Hydrochloride

Dosage Form: Solution for Injection

Specification: 200 mg per vial

Manufacturer: Eli Lilly and Company India Pvt Ltd

Indications: This product is indicated for the treatment of the following conditions:

Locally advanced or metastatic non-small cell lung cancer;

Locally advanced or metastatic pancreatic cancer;

In combination with paclitaxel, gemcitabine is indicated for the treatment of unresectable, locally recurrent, or metastatic breast cancer that has relapsed following adjuvant/neoadjuvant chemotherapy. Unless clinically contraindicated, prior chemotherapy regimens should have included an anthracycline antibiotic.

Dosage and Administration: The recommended dose of gemcitabine for adults is 1000 mg/m², administered as a 30-minute intravenous infusion once weekly for three consecutive weeks, followed by a one-week rest period; this four-week cycle is then repeated. The dosage should be reduced as appropriate based on the patient's toxic reactions. Elderly Patients: Elderly patients aged 65 years and older generally tolerate the treatment well. Although age may influence the clearance rate and half-life of gemcitabine, there is no evidence to suggest that dosage adjustment is required for elderly patients.